Traditional cardiovascular drugs like lipid-lowering agents and renin-angiotensin system blocking drugs have proven to be unsuccessful in retarding the progression of CAVD in clinical trials. This evidence concerns the gene REN and congenital bilateral aplasia of vas deferens from CFTR mutation.